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Abstract
The spread of aac(6’)-Ib-cr plasmid-mediated quinolone resistance determinants was evaluated in 197
enterobacterial isolates recovered in an Italian teaching hospital. The aac(6’)-Ib-cr gene was found exclusively in
Escherichia coli strains. The gene was located on a plasmid which presented additional ESBL genes. Most of the
clinical strains were clonally related and displayed three point mutations at the topoisomerase level which
conferred high resistance to fluoroquinolones.
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Findings
The aminoglycoside acetyltransferase Aac(6’)-Ib-cr var-
iant, an enzyme usually encoded by a plasmid-borne
gene, extends its drug targets to include fluoroquinolones
(FQs) in addition to aminoglycosides. It is characterized
by amino acid changes at codon 102 (Trp®Arg) and
codon 179 (Asp®Tyr). The Aac(6’)-Ib-cr protein is able
to specifically acetylate hydrophilic FQs presenting a free
piperazinyl amine (i.e. ciprofloxacin and norfloxacin) [1].
The aac(6’)-Ib-cr gene has spread rapidly among Enter-
obacteriaceae, and although only conferring a low-level
resistance, it may create an environment facilitating the
selection of more highly resistant determinants, especially
those harbouring topoisomerase mutations. This fact is
particularly worrisome at the nosocomial level, where
aac(6’)-Ib-cr containing strains should be promptly
detected and treated with non-hydrophilic FQs, such as
levofloxacin or ofloxacin, or other classes of antibiotics to
prevent high-level resistance onset and spread.
In this work we determined the prevalence of the aac
(6’)-Ib-cr gene variant among clinical isolates of Entero-
bacteriacea collected at the teaching Hospital of Padua,
Italy. In the time period of March-May 2008, 197 non-
duplicate clinical isolates were collected. These displayed
the whole range of MIC of ciprofloxacin; in particular,
104 samples were susceptible (MIC ≤ 1), 35 intermediate
(1 < MIC < 4), and 58 resistant (MIC ≥ 4) to ciprofloxa-
cin. Exact MIC values were measured by means of E-test
strips (AB Biodisk, Solna, Sweden). Bacterial isolates
were: 145 E. coli,3 8K. pneumoniae,5Proteus mirabilis,
5 Enterobacter aerogenes,2Enterobacter cloacae and 2
Citrobacter freundii. Sample identity and results are
reported in Table 1.
T h ep r e s e n c eo ft h eaac(6’)-Ib or aac(6’)-Ib-cr genes
was assessed by PCR amplification and subsequent
sequencing with primers: aacF 5’-ATGACTGAGCAT-
GACCTTG-3’;a a c R5 ’-AACCATGTACACGGCTGG-3’;
aacSEQ 5’-CGTCACTCCATACATTGCAA-3’ [2].
Twenty-five samples out of 197 (13%) were positive for
the aac(6’)-Ib gene and of these 16 (8%) displayed the aac
(6’)-Ib-cr variant. In particular, aac(6’)-Ib-cr was found
exclusively in E. coli, while aac(6’)-Ib was present mostly
in K. pneumoniae (8 K. pneumoniae,1E. coli). Out of the
16 aac(6’)-Ib-cr-positive samples, 15 were collected from
urine and 1 from skin; 13 were from inpatients (81%) and
3 from outpatients.
All aac(6’)-Ib were tested for other plasmid-mediated
quinolone-resistence genes, i.e. qnr and qepA,b yP C R
amplification and sequencing using published procedures
[3]. None of these was found in the aac(6’)-Ib-cr-positive
samples, while 5 out of 9 aac(6’)-Ib-positive strains pre-
sented the qnrB19 gene, indicating that just one of the
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any medium, provided the original work is properly cited.Table 1 Properties of aac(6’)-Ib-positive clinical isolates and transformant and transconjugant strains
Isolate
ID
Bacterial species qnr
gene
aac(6’) -Ib
gene
MIC (mg/L) GyrA ParC ESBL
i
phen
ESBL
genotypic
ERIC
NA
d CPF
e OFX
f LVF
g MXF
h
6 Escherichia coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V - - 1
6T
a E. coli TOP10 cr - 0.008 0.008 0.016 0.004 0.006 - - nd -
13 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V - CTX-M-1 1
13C
b J53AzKanNaR cr - 0.064 0.064 0.047 0.047 0.023 - - nd CTX-M-1
13T E. coli TOP10 cr - 0.008 0.008 0.016 0.004 0.006 - - nd CTX-M-1
19 E. coli non-cr -n d n d n d n d
23 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1+TEM-
1
2
23C J53AzKanNaR cr - 0.047 0.047 0.047 0.047 0.032 - - nd CTX-M-1+TEM-
1
23T E. coli TOP10 cr - 0.004 0.004 0.016 0.004 0.006 - - nd CTX-M-1+TEM-
1
37 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
37T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1+TEM-
1
39 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1 3
39T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1
40 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
40T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1+TEM-
1
44 E. coli cr - 0.047 0.047 0.032 0.047 0.023 - - X CTX-M-1 3
44C J53AzKanNaR cr - 0.047 0.047 0.047 0.047 0.023 - - nd CTX-M-1
44T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1
51 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1 1
51T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1
52 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1 1
52T E. coli TOP10 cr - 0.004 0.004 0.016 0.004 0.006 - - nd CTX-M-1
53 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1 1
53T E. coli TOP10 cr - 0.004 0.004 0.016 0.004 0.006 - - nd CTX-M-1
111 Klebsiella
pneumoniae
non-cr qnrB19 1.5 1.5 4 2 nd nd nd X TEM-1+SHV-12
128 K. pneumoniae non-cr - 1.5 1.5 3 2 2 nd nd nd nd
137 K. pneumoniae non-cr qnrB19 1 1 4 1.5 1.5 nd nd X TEM-1
143 K. pneumoniae non-cr qnrB19 1.5 1.5 4 1.5 1.5 nd nd - TEM-150+SHV-
12
144 K. pneumoniae non-cr qnrB19 1.5 1.5 6 1.5 1.5 nd nd X TEM-150
164 E. coli cr - ≥ 4 ≥ 4 ≥ 16 ≥ 16 ≥ 16 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
164T E. coli TOP10 cr - 0.004 0.004 0.016 0.004 0.006 - - nd CTX-M-1
175 E. coli cr - ≥ 4 ≥ 4n d≥ 8 ≥ 8 S83L,
D87N
E84V X CTX-M-1 1
175T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1
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was acquired/maintained in the clinical isolates.
T h ep r e s e n c eo fm e c h a n i s m s of chromosomial resis-
tance to FQ was assessed on aac(6’)-Ib-cr-positive
strains. The genotypic analysis, performed with universal
primers [4], revealed that all samples, but #44, coded for
two mutations in GyrA (S83L, D87N) and one mutation
in ParC (E84V). Phenotypic analysis of resistance to
nalidixic acid and FQs confirmed the above results: 15
samples were resistant to all tested drugs, while one
(#44) was fully susceptible.
The presence of resistance to other classes of antibio-
tic was next assessed. Genotypic analysis of ESBL and
AmpC genes was performed by PCR amplification using
specific primers for the detection of ESBL, i.e. blaSHV,
blaTEM,b l a CTX-M-1, 2, 8, 9, and AmpC genes, i.e. blaMOX-
1, 2, blaCMY-1-11, blaLAT-1-4, blaBIL-1, blaDHA-1, 2, blaACC,
blaMIR-1T, blaACT-1, blaFOX-1, 5b [5-8]. Fifteen out of 16
samples presented the CTX-M-1 gene, which was
coupled with TEM-1 in 7 strains. No other bla genes,
or AmpC were detected. ESBL production, phenotypi-
cally measured according to the CLSI M100-S18 and
M2-A9 documents [9], was detected in 14 out of 16
samples. Accordingly, most of the samples were resis-
tant to b-lactams, while they retained susceptibility to
amikacin, imipenem, piperacillin/tazobactam; an equal
number of samples resistant and susceptible to gentami-
cin, trimethoprim/sulfamethoxazole, ceftazidime, cefe-
pime, aztreonam and tetracycline was detected (data not
shown).
Plasmid DNA was extracted from aac(6’)-Ib-cr-positive
strains and run on agarose gel, to confirm the presence
of the aac(6’)-Ib-cr gene on a mobile element: all sam-
ples presented two main electrophoretic band corre-
sponding to > 100 Kbp and 25 Kbp (Figure 1A). In each
case the aac(6’)-Ib-cr gene was located in the > 100 Kbp
band, as demonstrated by PCR gene amplification, using
DNA extracted from each band as template. Plasmid
localization of the aac(6’)-Ib-cr gene was further con-
firmed by successful transformation into E. coli Top10
strain of all 16 sample-plasmid DNA, extracted accord-
ing the Kieser protocol [10]. Transferability of the resis-
tance gene of three clinical isolates was tested by
conjugation in a kanamycin/sodium azide resistant E.
coli J53 strain [3]. All three samples were successfully
conjugated. The presence of the aac(6’)-Ib-cr was con-
firmed by PCR in both transformants and transconju-
gants. In addition, the ESBL genes previously detected
in the clinical isolate were always found on the same
plasmid as the aac(6’)-Ib-cr gene: just in one case (sam-
ple #164) TEM-1 was not co-transformed along with
aac(6’)-Ib-cr and CTX-M-1.
Table 1 Properties of aac(6?’?)-Ib-positive clinical isolates and transformant and transconjugant strains (Continued)
176 K. pneumoniae non-cr qnrB19 1 1 2 1.5 ≥ 8 nd nd - TEM-150
178 E. coli cr - ≥ 4 ≥ 4n d≥ 8 ≥ 8 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
178T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1+TEM-
1
180 K. pneumoniae non-cr - 0.25 0.25 0.75 0.25 0.38 nd nd X nd
182 E. coli cr - ≥ 4 ≥ 4 ≥ 8 ≥ 8 ≥ 8 S83L,
D87N
E84V X CTX-M-1 1
182T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1
183 Enterobacter
aerogenes
non-cr - 0.75 0.75 2 1 0.75 nd nd nd nd
184 E. coli cr - ≥ 4 ≥ 4n d≥ 8 ≥ 8 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
184T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 nd CTX-M-1+TEM-
1
185 E. coli cr - ≥ 4 ≥ 4n d≥ 8 ≥ 8 S83L,
D87N
E84V X CTX-M-1+TEM-
1
1
185T E. coli TOP10 cr - 0.006 0.006 0.016 0.004 0.006 - - nd CTX-M-1+TEM-
1
E. coli TOP10 - - 0.016 0.016 0.047 0.047 0.023 - - nd -
J53AzKanR - - 0.002 0.002 0.016 0.004 0.006 - - nd -
aT = tranformant strain;
bC: transconjugant strain.
dNA = nalidixic acid,
eCPF = ciprofloxacin,
fOFX = ofloxacin,
gLVF = levofloxacin,
hMXF = moxifloxacin.
iESBL
phen = ESBL phenotypic determination.
nd = not determined
- = negative
Resistance ranges: nalidixic acid S ≤ 16 mg/L, R ≥ 32 mg/L; ciprofloxacin S ≤ 1 mg/L, I = 2 mg/L, R ≥ 4 mg/L; ofloxacin, levofloxacin, moxifloxacin S ≤ 2 mg/L, I =
4 mg/L, R ≥ 8 mg/L.
Frasson et al. Gut Pathogens 2011, 3:12
http://www.gutpathogens.com/content/3/1/12
Page 3 of 5MIC analysis of FQs in transformants and tranconju-
gants compared to the wild type isolates showed a drastic
decrease in the MIC values of all tested antibiotics. How-
ever, MIC of ciprofloxacin increased of 2-4 times in trans-
formants and transconjugats, compared to the wild type
recipient strains, E. coli Top10 and J53. These results are
in line with the notion that the aac(6’)-Ib-cr alone does
not confer high level resistance to the drugs, but it stimu-
lates chromosomal mutations on the FQ targets, i.e. gyrase
and topoisomerase IV, which in turn dramatically increase
resistance to these drugs.
To assess the clonal relationship between aac(6’)-Ib-
cr-positive isolates, the “enterobacterial repetitive inter-
genic consensus” (ERIC)-PCR genomic DNA profiles
was analysed with specific primers [5]. Three different
main subgroups were identified (Figure 1B). Most aac
(6’)-Ib-cr-positive samples were clonally related (82%),
while 1 (6%) (#23) and 2 (12%) (#39 and #44) samples
belonged to two different subgroups (Table 1).
We have shown for the first time the presence of the
aac(6’)-Ib-cr gene limited to E. coli species in North-East
Italy. Like other plasmid-mediated resistance genes, i.e.
qnr,t h eaac(6’)-Ib-cr gene does not significantly incre-
ment MIC values, but it seriously increases the mutant
prevention concentration (MPC) with final production of
remarkably resistant strains upon treatment with stan-
dard FQ dosage [1]. Indeed, we found that all but one
clinical isolate presented three mutations at the topoi-
somerase level (2 in GyrA and 1 in ParC) with conse-
quent generation of very resistant strains (MIC of
ciprofloxacin ≥ 32). These mainly derived by clonal
expansion, as demonstrated by ERIC subgrouping. Inter-
estingly, sample #44 did not show any mutation in the
topoisomerase genes, and so retained full susceptibility to
FQs. However, #44 resulted clonally related to sample
#39 which instead was fully resistant, indicating that
transition from susceptibily to resistance probably
occurred in a very limited time interval.
Finally, aac(6’)-Ib-cr-positive strains, which were
strongly associated with ESBL, were collected mainly by
inpatients and the proven plasmid localization and con-
jugation underline a very efficient mechanism of
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Figure 1 aac(6’)-Ib-cr-positive strain analysis. A) Analysis of plasmids extracted from aac(6’)-Ib-cr-positive strains by the Kieser method.
Plasmids were run on 0.7% TAE agarose gel at 50 V for 5 h. The numbers above each lane indicate the clinical strains ID. M stands for marker.
B) Clonal relationship based on the repetitive element PCR fingerprinting method, using “enterobacterial repetitive intergenic consensus” (ERIC)
primers. Amplified PCR products representative of the three identified subgroups were loaded on 1% TAE agarose gels and run at 100 V for 2 h.
Both gels were stained with ethidium bromide.
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Therefore, the presence of aac(6’)-Ib-cr-positive strains
must be promptly detected and referred to clinicians in
order to avoid use of FQs which would augment drug
resistance and impair therapy.
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